Top Stories
Ned Sharpless on Trump admin's shortlist to lead FDA: reportFulcrum cuts 85% of workforceInnoCare's BTK inhibitor clears mid-stage lupus trialEU approves paediatric label for Chiesi's LoxujtaNed Sharp...
More than a third of patients with primary membranous nephropathy taking the anti-CD20 mAb achieved clinical remission after 104 weeks.
The mineralocorticoid receptor antagonist slowed eGFR decline and cut cardiorenal risk across diverse non-diabetic chronic kidney disease (CKD) subtypes.
The legal provision of JPY 402.5 billion ($2.5 billion) in the financial year ended March 31 covers damages recently awarded by a US jury in a case related to generic versions of of the constipation treatment Amitiza (lubiprostone).
OliX Pharmaceuticals secured fresh capital worth roughly $71 million, while the UK's FRɑ-targeting antibody-drug conjugate became the first new NHS treatment in over 20 years recommended for resistant ovarian cancer.
Conference News
New data from Phase 2 ZUPREME-1 trial at the AmericanPress release – No. 13 / 2026 Clinically meaningful, double-digit weight loss demonstrated through week 42Placebo-like tolerability observed and lo...
CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026New preclinical data demonstrate robust weight red...
Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecul...
- Preclinical NHP data demonstrate significant fat‑specific weight loss with RV‑8451, while preserving lean mass and showing no gastrointestinal adverse events -- IND‑enabling studies advancing, with ...
New EULAR 2026 data show CIMZIA® (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levelsNew in vitro and electron microscope data provide ...
